BEIJING, June 27 (Xinhua) -- Jiangxi Synergy Pharmaceutical Co., Ltd. (300636. SZ) announced late Wednesday that it had received a Good Manufacturing Practice (GMP) certificate from the Brazilian Health Regulatory Agency (Anvisa), meaning that its 11 active pharmaceutical ingredients (APIs) had passed the GMP on-site inspection by the agency.
The China-based pharmaceutical company underwent a comprehensive GMP inspection by Anvisa from April 8 to 13, 2024, with its 11 APIs involved in the inspection.
Brazil Good Manufacturing Practice (GMP) standards are key regulatory benchmarks in Brazil and apply to the manufacturing of medical products, pharmaceuticals, and food.
According to the announcement, the certificate from Anvisa will pave the way for its 11 API products to enter the Brazilian market, playing a positive role for its business expansion in the country.
Jiangxi Synergy Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company and is engaged in research, development, production and sales of chemical raw materials and pharmaceutical intermediates. (Edited by Wu Rui, hupingchao@xinhua.org)
A single purchase
